Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients

被引：0
|
作者：
Dilara Akhoundova Sanoyan
Katja Seipel
Ulrike Bacher
Marie-Noelle Kronig
Naomi Porret
Gertrud Wiedemann
Michael Daskalakis
Thomas Pabst
机构：
[1] Inselspital,Department of Medical Oncology
[2] University Hospital of Bern,Department for Biomedical Research
[3] Center for Hemato-Oncology; University Cancer Center,Department of Hematology and Central Hematology Laboratory
[4] University of Bern,Clinical Genomics Lab
[5] Inselspital,undefined
[6] Bern University Hospital,undefined
[7] University of Bern,undefined
[8] Inselspital,undefined
[9] University Hospital of Bern,undefined
来源：
BMC Cancer | / 23卷
关键词：
Myeloma; CAR-T; Relapsed; Outcome; Ide-cel;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
    Sanoyan, Dilara Akhoundova
    Seipel, Katja
    Bacher, Ulrike
    Kronig, Marie-Noelle
    Porret, Naomi
    Wiedemann, Gertrud
    Daskalakis, Michael
    Pabst, Thomas
    BMC CANCER, 2023, 23 (01)
  • [2] Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
    Mancuso, Katia
    Barbato, Simona
    Talarico, Marco
    Tacchetti, Paola
    Zamagni, Elena
    Cavo, Michele
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 27 - 46
  • [3] Single-center experience with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma
    Sanoyan, D. Akhoundova
    Bacher, U.
    Kronig, M. -N.
    Seipel, K.
    Daskalakis, M.
    Pabst, T.
    SWISS MEDICAL WEEKLY, 2022, 152 : 64S - 64S
  • [4] Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma
    Anderson, Larry D., Jr.
    FUTURE ONCOLOGY, 2021, 18 (03) : 277 - 289
  • [5] Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
    Sidana, Surbhi
    Ahmed, Nausheen
    Akhtar, Othman S.
    Heim, Michael
    Brazauskas, Ruta
    Hansen, Doris K.
    Ferreri, Christopher
    Freeman, Ciara Louise L.
    Afrough, Aimaz
    Anderson, Larry D., Jr.
    Dhakal, Binod
    Dhanda, Devender
    Gowda, Lohith
    Hashmi, Hamza
    Harrison, Melanie
    Kitali, Amani
    Mirza, Sayeef
    Patel, Jinalben
    Patwardhan, Pallavi
    Usmani, Saad Z.
    Patel, Krina K.
    Ganguly, Siddhartha
    Pasquini, Marcelo
    BLOOD, 2023, 142
  • [6] Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.
    Hansen, Doris K.
    Sidana, Surbhi
    Peres, Lauren
    Shune, Leyla
    Sborov, Douglas W.
    Hashmi, Hamza
    Kocoglu, Mehmet H.
    Atrash, Shebli
    Simmons, Gary
    Kalariya, Nilesh
    Ferreri, Christopher J.
    Afrough, Aimaz
    Kansagra, Ankit J.
    Voorhees, Peter M.
    Alsina, Melissa
    McGuirk, Joseph
    Locke, Frederick L.
    Patel, Krina K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma
    Cavo, Michele
    HAEMATOLOGICA, 2023, 108 (08) : 1988 - 1990
  • [8] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-Cell therapy, in patients with relapsed and refractory multiple myeloma: Updated KarMMa results
    Einsele, H.
    Oriol, A.
    San-Miguel, J.
    Kansagra, A.
    Madduri, D.
    Shah, N.
    Moreau, P.
    Yakoub-Agha, I
    Delforge, M.
    Cavo, M.
    Goldschmidt, H.
    Weisel, K.
    Rambaldi, A.
    Reece, D.
    Rodriguez-Otero, P.
    Petrocca, F.
    Connarn, J. N.
    Patel, P.
    Huang, L.
    Campbell, T. B.
    Hege, K.
    Munshi, N. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 120 - 121
  • [9] EVALUATION OF HEALTH STATUS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), CAR T CELL THERAPY AGAINST BCMA
    Paula, Rodriguez-Otero
    Michel, Delforge
    Nina, Shah
    Parames-Waran, Hari
    Julia, Braverman
    Andrew, Trigg
    Payal, Patel
    Liping, Huang
    Kristen, Hege
    Sujith, Dhanasiri
    HAEMATOLOGICA, 2021, 106 (10) : 287 - 288
  • [10] Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
    Munshi, Nikhil C.
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus G.
    Lonial, Sagar
    Raje, Noopur S.
    Siegel, David Samuel DiCapua
    Lin, Yi
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Petrocca, Fabio
    Connarn, Jamie
    Patel, Payal
    Huang, Liping
    Campbell, Timothy Brandon
    Hege, Kristen
    San Miguel, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345